CV vs PHG vs POSC Stock Comparison

CapsoVision, Koninklijke Philips and Positron Prices as of Oct 26, 2026 Peers: Industry group
CV CapsoVision, Inc
$6.89 +3.6% 1M +40.6% 1Y
Market cap
$344.72M
P/E
–
Revenue (TTM)
$14.41M
Div. yield
–
Diagnostic Equipment Healthcare
1 win
PHG Koninklijke Philips Nv
$26.56 +6.4% 1M -7.9% 1Y
Market cap
$25.58B
P/E
13.7x
Revenue (TTM)
$20.60B
Div. yield
3.73%
Diagnostic Equipment Healthcare
4 wins
POSC Positron Corp
$1.70 -8.1% 1M +9.7% 1Y
Market cap
$55.84M
P/E
–
Revenue (TTM)
$462.27K
Div. yield
–
Diagnostic Equipment Healthcare
3 wins

Head to Head

8 decided of 12

Koninklijke Philips leads on 4 of the 12 questions below (Koninklijke Philips 4, Positron 3, CapsoVision 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCVPHGPOSCLeader
Larger companyMarket capitalisation $344.72M $25.58B $55.84M PHG
Cheaper on earningsLower P/E, profitable companies only -12.5x 13.7x -11.4x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 13.4x — –
Faster revenue growthRevenue growth, trailing twelve months +14.6% +6.1% +202.2% POSC
More profitableNet margin, trailing twelve months -190.2% 8.9% -1,060.5% PHG
Better return on capitalReturn on invested capital — 11.5% — –
Less leveragedLower net debt / EBITDA — 1.8x -0.3x POSC
Higher dividend yieldTrailing dividend yield 0.00% 3.73% — –
Better 1-year returnPrice return, last 12 months +40.6% -7.9% +9.7% CV
Better 5-year returnAnnualised price return, 5 years — -10.8%/yr +23.2%/yr POSC
Less volatileAnnualised volatility, 1 year 96.1% 28.8% 86.9% PHG
Higher overall scoreMean of the five percentile scores vs peers 36/100 80/100 13/100 PHG

Percentile Scorecard

CVPHGPOSC

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCVPHGPOSC
Valuation 5 #217 of 228 98 #6 of 228 21 #181 of 228
Growth 42 #128 of 221 96 #11 of 221 18 #181 of 221
Profitability 23 #161 of 208 96 #10 of 208 4 #200 of 208
Financial Health 76 #59 of 239 31 #166 of 239 4 #229 of 239
Shareholder Returns – 79 #29 of 137 18 #112 of 137
Overall 36 80 13
  • CV ranked among 248 companies in Medical Devices and Diagnostics
  • PHG ranked among 248 companies in Medical Devices and Diagnostics
  • POSC ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCVPHGPOSCSPY
1 month +3.6%+6.4%-8.1% -0.8%
3 months +4.2%+6.2%+8.3% +3.5%
6 months +8.2%-3.6%-11.9% +7.0%
Year to date -35.5%-1.9%+1.8% +12.2%
1 year +40.6%-7.9%+9.7% +13.0%
3 years —+43.6%+36.0% +86.3%
3 years, per year —+12.8%+10.8% +23.1%
5 years —-43.6%+183.3% +68.6%
5 years, per year —-10.8%+23.2% +11.0%
10 years —-11.6%+5,566.7% +258.0%
10 years, per year —-1.2%+49.7% +13.6%

Risk

MeasureCVPHGPOSCSPY
Volatility, 1Y 96.1%28.8%86.9% 12.7%
Downside volatility, 1Y 89.7%28.8%87.5% 12.7%
Beta vs S&P 500, 1Y 0.620.810.28 1.00
Return / volatility, 1Y 0.42-0.270.11 1.02
Max drawdown, 5Y -67.8%-75.6%-65.6% -25.4%
From 52-week high -52.2%-19.3%-33.6% -1.8%
52-week high $14.42$32.91$2.56 $779.14
52-week low $4.59$23.81$1.31 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCVPHGPOSC
P/E now vs peer median -12.5xmedian 30.6x 13.7xmedian 30.6x -11.4xmedian 30.6x
P/S now vs peer median 23.9xmedian 3.0x 1.2xmedian 3.0x 120.8xmedian 3.0x
EV/EBITDA now vs peer median -12.5xmedian 17.5x 8.1xmedian 17.5x -12.1xmedian 17.5x
P/FCF now vs peer median —median 23.3x 5.9xmedian 23.3x -13.4xmedian 23.3x
P/B now vs peer median 26.2xmedian 2.4x 2.0xmedian 2.4x -84.5xmedian 2.4x
PEG now vs peer median —median 0.87 0.32median 0.87 —median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCVPHGPOSC
Revenue $14.41M $20.60B $462.27K
Gross profit $7.55M $16.03B -$1.33M
Operating income -$27.71M $2.65B -$4.82M
Net income -$27.42M $1.39B -$4.90M
Free cash flow – $4.34B -$4.16M
R&D $20.51M $2.00B –
EPS (diluted) $-0.55 $1.91 $-0.15
Cash & equivalents – $2.04B $357.17K
Total debt – $9.51B $2.00M
Shares (diluted) 49.94M 962.50M 32.85M
Enterprise value $344.72M $14.72B $48.56M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCVPHGPOSC
P/E -12.5x 13.7x -11.4x
P/FCF – 5.9x -13.4x
P/Operating cash flow – 9.6x -13.4x
P/S 23.9x 1.2x 120.8x
P/B 26.2x 2.0x -84.5x
P/Tangible book 26.2x 2.5x -84.5x
EV/EBITDA -12.5x 8.1x -12.1x
EV/EBIT -12.4x 12.4x -11.9x
EV/Revenue 23.9x 1.6x 124.3x
EV/FCF – 7.6x -13.8x
EV/Operating cash flow – 12.4x -13.8x
PEG (3Y EPS CAGR) – 0.32 –

Growth

14 metrics
MetricCVPHGPOSC
Revenue growth (1Y) 14.6% 6.1% 202.2%
Revenue CAGR (3Y) – 2.3% –
Gross profit growth (1Y) 11.1% 82.4% -15.2%
Gross profit CAGR (3Y) – 6.7% –
Operating income growth (1Y) -36.1% 121.3% -17.5%
Operating income CAGR (3Y) – 52.0% –
Net income growth (1Y) -34.9% 293.5% -18.0%
Net income CAGR (3Y) – 35.6% –
EPS growth (1Y) 93.8% 539.4% -12.5%
EPS CAGR (3Y) – 42.2% –
Operating cash flow growth (1Y) – 116.7% -17.0%
Operating cash flow CAGR (3Y) – 53.6% –
Free cash flow growth (1Y) – 54.2% -17.0%
Free cash flow CAGR (3Y) – 45.6% –

Profitability

14 metrics
MetricCVPHGPOSC
Gross margin 52.4% 77.8% -288.1%
EBITDA margin -190.7% 19.8% -1,030%
Operating margin -192.3% 12.9% -1,042%
Pretax margin -190.1% 11.9% -1,060%
Net margin -190.2% 8.9% -1,060%
FCF margin – 21.1% -900.4%
Operating cash flow margin – 12.9% -900.4%
Return on equity -207.5% 12.7% –
Return on assets -149.3% 5.4% -216.9%
Return on invested capital – 11.5% –
Return on capital employed -209.8% 11.8% -61,094%
Asset turnover 0.8x 0.7x 0.2x
Cash conversion (OCF / net income) – 1.9x 0.8x
Stock comp / revenue – 0.7% –

Financial Health

11 metrics
MetricCVPHGPOSC
Debt / assets – 31.2% 115.8%
Debt / equity – 0.7x -3.0x
Net debt / EBITDA – 1.8x -0.3x
Debt / FCF – 2.2x -0.5x
Liabilities / assets 29.1% 57.1% 138.2%
Equity / assets 70.9% 42.9% -38.2%
Interest coverage – 6.2x -43.8x
Current ratio 3.4x 1.3x 0.5x
Quick ratio – 0.7x 0.2x
Cash ratio – 0.2x 0.2x
Altman Z-score 22.08 – -114.88

Shareholder Returns

7 metrics
MetricCVPHGPOSC
Dividend yield – 3.7% –
Net buyback yield – -0.5% -5.4%
Shareholder yield 0.0% 3.3% -5.4%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCVPHGPOSC
Forward P/E – 13.4xFY2026 –
EPS, next fiscal year $-0.58FY2026 $1.98FY2026 –
EPS growth, next FY – +6.5%FY2026 –
EPS growth, the year after – -10.1% –
Revenue, next fiscal year $13.91MFY2026 $21.63BFY2026 –
Revenue growth, next FY +2.7%FY2026 +1.8%FY2026 –
Revenue growth, the year after +46.0% -8.2% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCVPHGPOSC
Held by institutions 10.2% 5.4% –
Institutions holding 50 363 –
Change in shares held, QoQ +27.6% +0.8% –
Institutions buying 36 266 –
Institutions selling 8 76 –
Buyers to sellers 4.50 3.50 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CVPHGPOSC
CV 1.00 -0.01 0.01
PHG -0.01 1.00 0.00
POSC 0.01 0.00 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CV, PHG and POSC?

Koninklijke Philips (PHG) is the largest by market capitalisation: CapsoVision (CV) $344.72M, Koninklijke Philips (PHG) $25.58B, Positron (POSC) $55.84M.

Which company is growing faster?

Positron (POSC) grew revenue fastest over the trailing twelve months: CapsoVision (CV) +14.6%, Koninklijke Philips (PHG) +6.1%, Positron (POSC) +202.2%.

Which company is more profitable?

Koninklijke Philips (PHG) has the highest net margin (CapsoVision (CV) -190.2%, Koninklijke Philips (PHG) 8.9%, Positron (POSC) -1,060.5%).

Which stock has performed better?

Over the past year CapsoVision (CV) returned the most: CapsoVision (CV) +40.6%, Koninklijke Philips (PHG) -7.9%, Positron (POSC) +9.7%. Over five years, Positron (POSC) compounded fastest (Koninklijke Philips (PHG) -10.8%/yr, Positron (POSC) +23.2%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: CapsoVision (CV) 0.00%, Koninklijke Philips (PHG) 3.73%. CapsoVision (CV) and Positron (POSC) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Koninklijke Philips (PHG) has been the steadiest (CapsoVision (CV) 96.1%, Koninklijke Philips (PHG) 28.8%, Positron (POSC) 86.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CV, PHG and POSC?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Koninklijke Philips (PHG) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.